125 Participants Needed

Olfactory Biopsies for Loss of Smell

MJ
BJ
Overseen ByBradley J Goldstein, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how the olfactory lining in the nose functions and changes under various conditions. Researchers collect nasal tissue samples (olfactory biopsy) to gain insights into smell, especially in individuals with Alzheimer's and those with smell disorders. Individuals with Alzheimer's or a history of smell loss after an infection, such as COVID-19, may be suitable for this study. Participants should not have allergies to specific medications used during the procedure or active sinus problems. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on smell disorders and Alzheimer's.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What prior data suggests that olfactory biopsies are safe?

Research has shown that taking a small tissue sample from the nose, known as an olfactory biopsy, is generally safe. Studies have found that this procedure does not affect a person's sense of smell. Specifically, one study found that individuals who underwent the biopsy had similar nasal function and smell as those who did not.

Some minor side effects have been reported, but they usually resolve quickly. For example, individuals might experience a brief backache or mild headache after the procedure. Overall, these studies suggest that the procedure is well-tolerated and does not negatively impact quality of life.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a novel method for diagnosing and understanding the loss of smell, especially in conditions like Alzheimer's and post-viral smell loss (such as COVID-19). Unlike traditional tests that only assess smell function, this method involves taking a small biopsy from the olfactory region of the nose using a nasal endoscope. This approach could provide deeper insights into the cellular changes associated with smell loss, potentially leading to better-targeted treatments in the future. By comparing groups with different causes of smell loss, the study aims to uncover unique patterns that could differentiate between types of smell dysfunction. This could pave the way for more personalized diagnostic and treatment strategies.

What evidence suggests that olfactory biopsies are effective for assessing loss of smell?

Research shows that taking small tissue samples from the nose can help researchers understand smell disorders. In past studies, samples from the part of the nose that detects smells have provided important information. The success rate for collecting this tissue ranges from 40% to 89%, demonstrating the feasibility of gathering and studying it. In this trial, participants will undergo olfactory biopsies to explore the causes and potential treatments for smell loss. People who lost their sense of smell due to upper respiratory infections like COVID-19 generally experience higher recovery rates compared to other causes. This suggests that this method could offer valuable insights into how smell loss occurs and how it might be treated.678910

Who Is on the Research Team?

BG

Bradley Goldstein, MD, PhD

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

This trial is for individuals with Alzheimer's Disease, Parosmia (distorted smell perception), or Anomia (difficulty naming odors). It involves those who have lost their sense of smell. Participants must be healthy enough to undergo a biopsy.

Inclusion Criteria

Patients being seen for rhinology or olfactory disorders
I am between 18 and 80 years old.
Pre-clinical AD (subjects with normal cognitive testing and function, but positive AD biomarkers)
See 5 more

Exclusion Criteria

Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)
I am unable to give legal consent by myself.
Alzheimer's study:
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Olfactory Function Assessment

Olfactory function is assessed using psychophysical testing such as the Smell Identification Test or Sniffin' Sticks Test

1-2 weeks
1 visit (in-person)

Biopsy Collection

Biopsies of the olfactory lining are obtained using a cytology brush or punch technique, potentially with odor stimulation

1 week
1 visit (in-person)

Analysis

Biopsies are processed for assays including histology, primary culture assays, flow cytometry assays, or transcriptomic profiling

Ongoing

Follow-up

Participants are monitored for any adverse effects post-biopsy and for data collection purposes

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Olfactory Biopsy
Trial Overview The study is testing how the olfactory lining in the nasal cavity functions by using odor stimulation and olfactory testing. Researchers will collect tissue samples from participants' nasal cavities to examine potential changes due to health conditions.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Alzheimer's studyExperimental Treatment3 Interventions
Group II: Act-seq study or Non-AD controlsExperimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Duke University

Lead Sponsor

Trials
2,495
Recruited
5,912,000+

National Institute on Deafness and Other Communication Disorders (NIDCD)

Collaborator

Trials
377
Recruited
190,000+

Citations

Investigations and Outcomes for Olfactory Disorders - PMCThis review highlights the key investigations and reasoning for their use to clinically assess and research patients with olfactory disorders.
Remote psychophysical testing of smell in patients with ...Using the OMT, impaired smell ability was detected in the vast majority of participants who contracted COVID-19. Persistent hyposmia or anosmia ...
Outcomes of olfaction in patients with empty nose ...In conclusion, surgical treatment is effective in improving olfaction in patients with ENS, in which olfactory dysfunction is a significant characteristic.
Biopsy of the olfactory epithelium from the superior nasal ...The success rates of obtaining OE in biopsies performed from the nasal septum vary between 40% to 89%.9, 10, 11, 12, 13, 14, 15 However, these ...
Characteristics of Olfactory Disorders in Relation to Major ...Our data suggest that (1) recovery rate was higher in URI olfactory loss than in olfactory loss from other causes; (2) likelihood of recovery seemed to decrease ...
6.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/27107010/
Safety of human olfactory mucosal biopsy for the purpose ...All Olfactory function outcomes were unaffected following olfactory biopsy. We demonstrated that the patients quality of life and nasal patency as well as ...
The observed adverse events following the olfactory ...The most common adverse events were transient backache and meningism (90%) and cord malacia (80%). The cell therapy method in which the treatment was associated ...
Drug-induced olfactory and gustatory dysfunctionRecently, in 2021, the FDA identified duloxetine (Cymblata) as having potential serious risks of anosmia and hyposmia, and further evaluation of regulatory ...
Safety of human olfactory mucosal biopsy for the purposeCurrent evidence suggests that human olfactory mucosal biopsies do not have a detrimental effect on the patient's sense of smell (5,6), however ...
10.discovery.ucl.ac.ukdiscovery.ucl.ac.uk/1530783/
A prospective, controlled study on 131 patients assessing ...The complication rate, the nasal function and the sense of smell outcomes of the biopsy group were statistically the same when compared to the control group. In ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security